Patents by Inventor James B. McMahon

James B. McMahon has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTI-VIRAL GRIFFITHSIN COMPOUNDS, COMPOSITIONS AND METHODS OF USE
    Publication number: 20100221242
    Abstract: A method of inhibiting a viral infection of a host comprising administering to the host an anti-viral griffithsin polypeptide comprising SEQ ID NO: 3 or a fragment thereof comprising at least eight contiguous amino acids, a nucleic acid encoding the anti-viral polypeptide, or an antibody to the anti-viral polypeptide. A method of inhibiting a virus in a sample comprising contacting the sample with an anti-viral griffithsin polypeptide or antibody thereto also is provided.
    Type: Application
    Filed: December 1, 2006
    Publication date: September 2, 2010
    Inventors: Barry R. O'Keefe, Toshiyuki Mori, James B. McMahon
  • Scytovirin Domain 1 Related Polypeptides
    Publication number: 20080311125
    Abstract: A scytovirin domain 1 (SD1) polypeptide, a nucleic acid encoding the polypeptide, and related fusion proteins, conjugates, isolated cells, vectors, and antibodies, as well as a method of inhibiting a viral infection using the same.
    Type: Application
    Filed: May 24, 2006
    Publication date: December 18, 2008
    Applicant: Office of Technology Transfer
    Inventors: Barry R. O'Keefe, Chang-yun Xiong, James B. McMahon, Andrew Byrd
  • Antiviral proteins and peptides, DNA coding sequences therefor, and uses thereof
    Patent number: 6987096
    Abstract: The present invention provides antiviral proteins (collectively referred to as cyanovirins), conjugates thereof, DNA sequences encoding such agents, host cells containing such DNA sequences, antibodies directed to such agents, compositions comprising such agents, and methods of obtaining and using such agents.
    Type: Grant
    Filed: November 13, 1997
    Date of Patent: January 17, 2006
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Michael R. Boyd, Kirk R. Gustafson, Robert H. Shoemaker, James B. McMahon
  • Calanolide and related antiviral compounds, compositions, and uses thereof
    Patent number: 6774141
    Abstract: The present invention provides novel antiviral compounds, refered to as calanolides, related compounds, and their derivatives, which may be isolated from plants, or derived from compounds from plants, of the genus Calophyllum in accordance with the present inventive method. The compounds and their derivatives may be used alone or in combination with other antiviral agents in compositions, such as pharmaceutical compositions, to inhibit the growth or replication of a virus, such as a retrovirus, in particular a human immunodeficiency virus, specifically HIV-1 or HIV-2.
    Type: Grant
    Filed: May 20, 1998
    Date of Patent: August 10, 2004
    Assignee: The United States of America as represented by the Secretary of Health and Human Services
    Inventors: Michael R. Boyd, John H. Cardellina, II, Kirk R. Gustafson, James B. McMahon, Richard W. Fuller, Gordon M. Cragg, Yoel Kashman
  • Calanolide and related antiviral compounds, compositions, and uses thereof
    Patent number: 6673830
    Abstract: The present invention provides novel antiviral compounds, refered to as calanolides, related compounds, and their derivatives, which may be isolated from plants, or derived from compounds from plants, of the genus Calophyllum in accordance with the present inventive method. The compounds and their derivatives may be used alone or in combination with other antiviral agents in compositions, such as pharmaceutical compositions, to inhibit the growth or replication of a virus, such as a retrovirus, in particular a human immunodeficiency virus, specifically HIV-1 or HIV-2.
    Type: Grant
    Filed: June 22, 2001
    Date of Patent: January 6, 2004
    Assignees: The United States of America as represented by the Secretary of Health and Human Services, The Board of Trustees of the University of Illinois
    Inventors: Michael R. Boyd, John H. Cardellina, II, Kirk R. Gustafson, James B. McMahon, Richard W. Fuller, Gordon M. Cragg, Yoel Kashman, Doel Soejarto
  • Calanolide and related antiviral compounds, compositions, and uses thereof
    Publication number: 20020086898
    Abstract: The present invention provides novel antiviral compounds, refered to as calanolides, related compounds, and their derivatives, which may be isolated from plants, or derived from compounds from plants, of the genus Calophyllum in accordance with the present inventive method. The compounds and their derivatives may be used alone or in combination with other antiviral agents in compositions, such as pharmaceutical compositions, to inhibit the growth or replication of a virus, such as a retrovirus, in particular a human immunodeficiency virus, specifically HIV-1 or HIV-2.
    Type: Application
    Filed: June 22, 2001
    Publication date: July 4, 2002
    Inventors: Michael R. Boyd, John H. Cardellina, Kirk R. Gustafson, James B. McMahon, Richard W. Fuller, Gordon M. Cragg, Yoel Kashman, Doel Soejarto
  • Conjugates of antiviral proteins or peptides and virus or viral envelope glycoproteins
    Patent number: 6245737
    Abstract: The present invention provides antiviral proteins, peptides and conjugates, as well as methods of obtaining these agents. The antiviral proteins, peptides and conjugates of the present invention can be used alone or in combination with other antiviral agents in compositions, such as pharmaceutical compositions, to inhibit the infectivity, replication and cytopathic effects of a virus, such as a retrovirus, in particular a human immunodeficiency virus, specifically HIV-1 or HIV-2, in the treatment or prevention of viral infection.
    Type: Grant
    Filed: August 19, 1998
    Date of Patent: June 12, 2001
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Michael R. Boyd, Kirk R. Gustafson, Robert H. Shoemaker, James B. McMahon
  • Anti-cyanovirin antibody
    Patent number: 5998587
    Abstract: The present invention provides antiviral proteins (collectively referred to as cyanovirins), conjugates thereof, DNA sequences ending such agents, host cells containing such DNA sequences, antibodies directed to such agents, compositions comprising such agents, and methods of obtaining and using such agents.
    Type: Grant
    Filed: November 13, 1997
    Date of Patent: December 7, 1999
    Assignee: The United States of America, represented by the Secretary of the Department of Health and Human Services
    Inventors: Michael R. Boyd, Kirk R. Gustafson, Robert H. Shoemaker, James B. McMahon
  • Antiviral naphthoquinone compounds, compositions and uses thereof
    Patent number: 5869522
    Abstract: The present invention provides novel antiviral naphthoquinone compounds, which may be isolated from plants of the genus Conospermum or synthesized chemically, in accordance with the present inventive methods. The antiviral naphthoquionone compounds, derivatives thereof, and prodrugs thereof, may be used alone or in combination with other antiviral agents in compositions, such as pharmaceutical compositions, to inhibit the growth or replication of a virus, such as a retrovirus, in particular a human immunodeficiency virus, specifically HIV-1 or HIV-2, in the treatment or prevention of viral infection.
    Type: Grant
    Filed: May 31, 1995
    Date of Patent: February 9, 1999
    Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services
    Inventors: Michael R. Boyd, John H. Cardelina, II, Kirk R. Gustafson, Laurent A. Decosterd, Ian Parsons, Lewis Pannell, James B. McMahon, Gordon M. Cragg
  • Calanolide and related antiviral compounds, compositions, and uses thereof
    Patent number: 5859049
    Abstract: The present invention provides novel antiviral compounds, refered to as calanolides, related compounds, and their derivatives, which may be isolated from plants, or derived from compounds from plants, of the genus Calophyllum in accordance with the present inventive method. The compounds and their derivatives may be used alone or in combination with other antiviral agents in compositions, such as pharmaceutical compositions, to inhibit the growth or replication of a virus, such as a retrovirus, in particular a human immunodeficiency virus, specifically HIV-1 or HIV-2.
    Type: Grant
    Filed: May 24, 1996
    Date of Patent: January 12, 1999
    Assignees: The United States of America as represented by the Department of Health and Human Services, The Board of Trustees of the University of Illinois
    Inventors: Michael R. Boyd, John H. Cardellina, II, Kirk R. Gustafson, James B. McMahon, Richard W. Fuller, Gordon M. Cragg, Yoel Kashman, Doel Soejarto
  • Antiviral proteins and peptides
    Patent number: 5843882
    Abstract: The present invention provides antiviral proteins, peptides and conjugates, as well as methods of obtaining these agents. The antiviral proteins, peptides and conjugates of the present invention can be used alone or in combination with other antiviral agents in compositions, such as pharmaceutical compositions, to inhibit the infectivity, replication and cytopathic effects of a virus, such as a retrovirus, in particular a human immunodeficiency virus, specifically HIV-1 or HIV-2, in the treatment or prevention of viral infection.
    Type: Grant
    Filed: April 27, 1995
    Date of Patent: December 1, 1998
    Assignee: The United States of America as Represented by the Department of Health and Human Services
    Inventors: Michael R. Boyd, Kirk R. Gustafson, Robert H. Shoemaker, James B. McMahon
  • Nucleic acids encoding antiviral proteins and peptides, vectors and host cells comprising same, and methods of producing the antiviral proteins and peptides
    Patent number: 5821081
    Abstract: The present invention provides antiviral proteins (collectively referred to as cyanovirins), conjugates thereof, DNA sequences encoding such agents, host cells containing such DNA sequences, antibodies directed to such agents, compositions comprising such agents, and methods of obtaining and using such agents.
    Type: Grant
    Filed: April 26, 1996
    Date of Patent: October 13, 1998
    Assignee: The United States of Americaa as represented by the Secretary of the Department of Health and Human Services
    Inventors: Michael R. Boyd, Kirk R. Gustafson, Robert H. Shoemaker, James B. McMahon
  • Antiretroviral naphthoquinone compounds compositions and uses thereof
    Patent number: 5783598
    Abstract: The present invention provides novel antiviral naphthoquinone compounds, which may be isolated from plants of the genus Conospermum or synthesized chemically, in accordance with the present inventive methods. The antiviral naphthoquionone compounds, derivatives thereof, and prodrugs thereof, may be used alone or in combination with other antiviral agents in compositions, such as pharmaceutical compositions, to inhibit the growth or replication of a virus, such as a retrovirus, in particular a human immunodeficiency virus, specifically HIV-1 or HIV-2, in the treatment or prevention of viral infection.
    Type: Grant
    Filed: March 8, 1996
    Date of Patent: July 21, 1998
    Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Sevices
    Inventors: Michael R. Boyd, John H. Cardellina, II, Kirk R. Gustafson, Laurent A. Decosterd, Ian Parson, Lewis Pannell, James B. McMahon, Gordon M. Cragg
  • Antiviral naphthoquinone compounds, compositions and uses thereof
    Patent number: 5672607
    Abstract: The present invention provides novel antiviral naphthoquinone compounds, which may be isolated from plants of the genus Conospermum or synthesized chemically, in accordance with the present inventive methods. The antiviral naphthoquionone compounds, derivatives thereof, and prodrugs thereof, may be used alone or in combination with other antiviral agents in compositions, such as pharmaceutical compositions, to inhibit the growth or replication of a virus, such as a retrovirus, in particular a human immunodeficiency virus, specifically HIV-1 or HIV-2, in the treatment or prevention of viral infection.
    Type: Grant
    Filed: January 29, 1993
    Date of Patent: September 30, 1997
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Michael R. Boyd, John H. Cardellina, II, Kirk R. Gustafson, Laurent A. Decosterd, Ian Parsons, Lewis Pannell, James B. McMahon, Gordon M. Cragg
  • Process of preparing michellamine compounds
    Patent number: 5654432
    Abstract: The present invention provides new antiviral compounds, i.e., michellamines and derivatives and pharmacologically acceptable salts thereof, methods for isolating such antiviral compounds from a plant species of the genus Ancistrocladus, antiviral compositions containing such antiviral compounds, and methods of using such antiviral compounds for treating patients with viral infections. The antiviral compounds of the present invention inhibit the reproduction and cytopathicity of human acquired immunodeficiency viruses.
    Type: Grant
    Filed: June 1, 1995
    Date of Patent: August 5, 1997
    Assignee: The United States of America, as represented by the Department of Health and Human Services
    Inventors: Michael R. Boyd, John H. Cardellina, II, Kirk P. Manfredi, John W. Blunt, Lewis K. Pannell, James B. McMahon, Robert J. Gulakowski, Gordon M. Cragg, Gerhard Bringmann, Duncan Thomas, Johnson Jato
  • Antiviral composition
    Patent number: 5599839
    Abstract: The present invention relates to an antiviral composition and to methods of treating patients with viral infections. The antiviral composition of the present invention comprises prostratin, a phorbol ester derivative, and a pharmaceutically acceptable carrier. The present composition while having antiviral activity does not have substantial tumor promoting activity and does not have other substantial adverse toxicological properties that would preclude its use in antiviral therapy.
    Type: Grant
    Filed: April 17, 1995
    Date of Patent: February 4, 1997
    Assignees: The United States of America as represented by the Department of Health and Human Services, Brigham Young University
    Inventors: Michael R. Boyd, Paul A. Cox, Gordon M. Cragg, Peter M. Blumberg, Nancy A. Sharkey, Junichi Ishitoya, James B. McMahon, John A. Beutler, Owen S. Weislow, John H. Cardellina, II, Krik R. Gustafson
  • Calanolide and related antiretroviral compounds, compositions, and uses thereof
    Patent number: 5591770
    Abstract: The present invention provides novel antiviral compounds, refered to as calanolides, related compounds, and their derivatives, which may be isolated from plants, or derived from compounds from plants, of the genus Calophyllum in accordance with the present inventive method. The compounds and their derivatives may be used alone or in combination with other antiviral agents in compositions, such as pharmaceutical compositions, to inhibit the growth or replication of a virus, such as a retrovirus, in particular a human immunodeficiency virus, specifically HIV-1 or HIV-2.
    Type: Grant
    Filed: May 21, 1993
    Date of Patent: January 7, 1997
    Assignees: The United States of America as represented by the Department of Health and Human Services, The Board of Trustees of the University of Illinois
    Inventors: Michael R. Boyd, John H. Cardellina, II, Kirk R. Gustafson, James B. McMahon, Richard W. Fuller, Gordon M. Cragg, Yoel Kashman, Doel Soejarto
  • Michellamine antiviral agents, compositions, and treatment methods
    Patent number: 5455251
    Abstract: The present invention provides new antiviral compounds, i.e., michellamines and derivatives and pharmacologically acceptable salts thereof, methods for isolating such antiviral compounds from a plant species of the genus Ancistrocladus, antiviral compositions containing such antiviral compounds, and methods of using such antiviral compounds for treating patients with viral infections. The antiviral compounds of the present invention inhibit the reproduction and cytopathicity of human acquired immunodeficiency viruses.
    Type: Grant
    Filed: April 19, 1993
    Date of Patent: October 3, 1995
    Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services
    Inventors: Michael R. Boyd, John H. Cardellina, II, Kirk P. Manfredi, John W. Blunt, Lewis K. Pannell, James B. McMahon, Robert J. Gulakowski, Gordon M. Cragg, Gerhard Bringmann, Duncan Thomas, Johnson Jato